Optimal therapy in hepatitis C virus liver transplant patients with direct acting antivirals.
about
Next Steps Toward Eradication of Hepatitis C in the Era of Direct Acting AntiviralsChallenging hepatitis C-infected liver transplant patientsConcise review: Interferon-free treatment of hepatitis C virus-associated cirrhosis and liver graft infectionMulticenter Experience with Boceprevir or Telaprevir to Treat Hepatitis C Recurrence after Liver Transplantation: When Present Becomes Past, What Lessons for Future?Hepatic decompensation/serious adverse events in post-liver transplantation recipients on sofosbuvir for recurrent hepatitis C virusReadmission following liver transplantation: an unwanted occurrence but an opportunity to actInterferon-free antiviral treatment of chronic hepatitis C in the transplant setting.Treat chronic hepatitis C virus infection in decompensated cirrhosis - pre- or post-liver transplantation? the ironic conundrum in the era of effective and well-tolerated therapy.Managing drug-drug interactions with new direct-acting antiviral agents in chronic hepatitis C.Potential Liver Transplant Recipients with Hepatitis C: Should They Be Treated Before or After Transplantation?Cost-effectiveness of Ombitasvir/Paritaprevir/Ritonavir, Dasabuvir+Ribavirin for US Post-Liver Transplant Recurrent Genotype 1 HCV.The impact of directly acting antivirals on the enzymatic liver function of liver transplant recipients with recurrent hepatitis C.The influence of immunosuppressants on direct-acting antiviral therapy is dependent on hepatitis C virus genotype.Successful Treatment of Oral Lichen Planus with Direct-Acting Antiviral Agents after Liver Transplantation for Hepatitis C Virus-Associated Hepatocellular Carcinoma.
P2860
Q26747561-EDBE216F-9ED6-4ECC-BC74-4854C526B776Q26765020-D24A50C0-D7F6-41C8-8856-9C950EA63049Q28075544-10B7FBC7-E0FF-475B-96D5-45F95CA9A4F7Q33426112-4EC4AA65-FAB3-4517-8B81-DE8BF5DF16A8Q36650834-64CAC77F-2166-479B-8ADE-AF942DB773B6Q37391709-0D261448-894C-44B5-8431-FBFB1E750284Q38416448-558B4436-2C23-43B3-AD96-9E6E7DC2186BQ38790455-468EC9D1-BFB2-4C49-B0A6-FB02D9AEABC5Q38929010-32D4677A-262E-477A-ABD2-49F3C87B0C15Q39203624-F1B97DEA-3701-4AE7-B5C1-14A8AC1AAC3CQ40271866-B6D5178C-45D7-467A-B645-70E06B06845CQ40473486-A8EF6AB3-352B-40B4-A5A2-9FDD00A371B5Q45325199-74C7BF0C-5AA2-4068-AC2E-04C2466635AEQ49395696-A3F386E6-9B49-4A96-A9ED-4F32B12F0C90
P2860
Optimal therapy in hepatitis C virus liver transplant patients with direct acting antivirals.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Optimal therapy in hepatitis C ...... with direct acting antivirals.
@en
type
label
Optimal therapy in hepatitis C ...... with direct acting antivirals.
@en
prefLabel
Optimal therapy in hepatitis C ...... with direct acting antivirals.
@en
P2093
P2860
P356
P1433
P1476
Optimal therapy in hepatitis C ...... with direct acting antivirals.
@en
P2093
Audrey Coilly
Bruno Roche
Didier Samuel
P2860
P356
10.1111/LIV.12728
P478
35 Suppl 1
P577
2015-01-01T00:00:00Z